ORX — Orexo AB Share Price
0.000.00%
Last trade - 00:00- SEK581.99m
- SEK884.79m
- SEK638.80m
- 15
- 18
- 64
- 21
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 9.88 | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 0.91 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -20.92% | ||
| Return on Equity | -101.5% | ||
| Operating Margin | -17.14% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | SEKm | 844.8 | 663.6 | 565 | 624.3 | 638.8 | 778.45 | 795.15 | -3.99% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | +57.75 | -86.11 | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Orexo AB is a Sweden-based company active within the pharmaceutical industry. It focuses primarily on the development of new, patented drugs by combining documented substances with technologies, and the new treatments for respiratory and inflammatory diseases. The Company has four commercialized products, several projects developed in partnership, as well as three development programs. The Company's registered products are: Abstral for the treatment of break through cancer pain, sold by ProStrakan Group plc in Europe, the United States and Canada; the sleeping pill Edluar, sold by Meda in the United States and Canada; as well as two products for the diagnosis of Helicobacter pylori which are being marketed by the subsidiary, Kibion AB. The Company operates through subsidiaries: Pharmacall AB, Noster System AB, Orexo UK, and Pharmakodex Ltd, among others. In December 2013, Kyowa Hakko Kirin Co., Ltd (KHK), with the licensed right to Abstral, commenced the launch of it in Japan.
Directors
- James Noble NEC (62)
- Nikolaj Soerensen PRE (47)
- Joseph DeFeo CFO (58)
- Robert DeLuca CEX (58)
- Johannes Doll EVP (40)
- Dennis Urbaniak EVP (52)
- Cecilia Coupland VOP (43)
- Robert Roenn VRD (43)
- Michael Sumner OTH (54)
- Henrik Kjaer Hansen DRC (43)
- Staffan Lindstrand DRC (59)
- Mary Christie IND (56)
- David Colpman IND (58)
- Kirsten Detrick IND (54)
- Charlotte Hansson IND (52)
- Fred Wilkinson IND (63)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- November 25th, 1994
- Public Since
- November 9th, 2005
- No. of Shareholders
- 6,623
- No. of Employees
- 116
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- OMX Nordic Exchange Stockholm
- Shares in Issue
- 35,229,566
- Address
- Rapsgatan 7E, UPPSALA, 751 05
- Web
- https://orexo.se/
- Phone
- +46 187808800
- Contact
- Lena Wange
- Auditors
- Ernst & Young AB
Upcoming Events for ORX
Q1 2024 Orexo AB Earnings Release
Q2 2024 Orexo AB Earnings Release
Similar to ORX
Biogaia AB
OMX Nordic Exchange Stockholm
BoneSupport Holding AB
OMX Nordic Exchange Stockholm
Calliditas Therapeutics AB
OMX Nordic Exchange Stockholm
Camurus AB
OMX Nordic Exchange Stockholm
Cline Scientific AB
OMX Nordic Exchange Stockholm
FAQ
What is the Orexo AB share price?
As of Today at 19:16 UTC, shares in Orexo AB are trading at SEK16.52. This share price information is delayed by 15 minutes.
How has the Orexo AB share price performed this year?
Shares in Orexo AB last closed at SEK16.52 and the price had moved by +17.66% over the past 365 days. In terms of relative price strength the Orexo AB share price has outperformed the FTSE Global All Cap Index by +10.46% over the past year.
What are the analyst and broker recommendations for Orexo AB?
The overall consensus recommendation for Orexo AB is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Orexo AB dividend yield?
Orexo AB does not currently pay a dividend.
Does Orexo AB pay a dividend?
Orexo AB does not currently pay a dividend.
When does Orexo AB next pay dividends?
Orexo AB does not currently pay a dividend.
How do I buy Orexo AB shares?
To buy shares in Orexo AB you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Orexo AB?
As of the previous close price of SEK16.52, shares in Orexo AB had a market capitalisation of SEK581.99m.
Where are Orexo AB shares listed?
Here are the trading details for Orexo AB:
- Country of listing: Sweden
- Exchange: STO
- Ticker Symbol: ORX
What kind of share is Orexo AB?
Based on an overall assessment of its quality, value and momentum Orexo AB is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Orexo AB share price forecast for 2024?
The analyst consensus target price for shares in Orexo AB is SEK50.00. That is 202.66% above the last closing price of SEK16.52.
Analysts covering Orexo AB currently have a consensus Earnings Per Share (EPS) forecast of -SEK2.68 for the next financial year.
What is the trend in the Orexo AB share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Orexo AB. Over the past six months, its share price has underperformed the FTSE Global All Cap Index by -4.2%.
As of the last closing price of SEK16.52, shares in Orexo AB were trading +3.27% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Orexo AB PE Ratio?
The Orexo AB PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at SEK16.52.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Orexo AB?
Orexo AB's management team is headed by:
- James Noble - NEC
- Nikolaj Soerensen - PRE
- Joseph DeFeo - CFO
- Robert DeLuca - CEX
- Johannes Doll - EVP
- Dennis Urbaniak - EVP
- Cecilia Coupland - VOP
- Robert Roenn - VRD
- Michael Sumner - OTH
- Henrik Kjaer Hansen - DRC
- Staffan Lindstrand - DRC
- Mary Christie - IND
- David Colpman - IND
- Kirsten Detrick - IND
- Charlotte Hansson - IND
- Fred Wilkinson - IND